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Injury of the renal tubulointerstitial compartment is
recognized to play an important role in hypertension. Its
damage may in turn, impair the activity of vasodepressor
systems, like the kallikrein–kinin, in blood pressure
regulation. The overload proteinuria model induces
tubulointerstitial injury with activation of the
renin–angiotensin system, but renal kallikrein and the
development of hypertension have not received special
attention. Sprague–Dawley rats received seven
intraperitoneal doses of bovine serum albumin (BSA) 2 g/day
under normosodic diet and were hydrated ad libitum. A
second group received a high potassium diet to stimulate
kallikrein production during the previous four weeks and
while under BSA administration. A third one received
potassium and BSA in the same schedule, but with the kinin
B2 receptor antagonist, HOE140, added during the protein
load phase. A control group received seven saline injections.
Kallikrein protein was detected by immune labeling on renal
sections and enzymatic activity in the urine. The BSA group
showed massive proteinuria followed by intense tubuloin-
terstitial damage. Blood pressure increased after the third
dose in BSA animals, remaining elevated throughout the
experiment, associated with significant reductions in renal
expression and urinary activity of kallikrein, compared with
controls. An inverse correlation was found between blood
pressure and immunohistochemistry and urinary activity of
kallikrein. Potassium induced a significant increase in both
urinary activity and renal kallikrein expression, associated
with significant reduction in blood pressure. The HOE140
antagonist blunted the antihypertensive effect of kallikrein
stimulation in proteinuric rats. Loss of renal kallikrein,
produced by tubulointerstitial injury, may participate in the
pathogenesis of the hypertension observed in this model.
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The involvement of the renal tubulointerstitium in glomer-
ular diseases is supported by clinical and experimental
data.1 The heterologous protein overload proteinuria rat
model has been used in studying the role of proteinuria
in progressive renal disease2–8 and although it is characterized
by important tubulointerstitial damage and upregulation
of the renin–angiotensin system,9 the presence and possible
causes of associated hypertension have not received special
attention.
The kallikrein–kinin cascade, one of the main vasodilator
systems, participates in renal vascular tone regulation and
water and sodium/potassium excretion.10 As tissue kallikrein
and kininogen are located in the connecting tubule and
collecting duct segments of the kidney, respectively, it is
reasonable to expect that tubulointerstitial damage may affect
their synthesis, storage and secretion, and thereby create
imbalances in arterial tone or volume homeostasis, both
important in blood pressure regulation. Previous experi-
ments performed in our laboratory have shown evidence for
a stimulatory effect of high potassium diet on renal kallikrein,
inducing hypertrophy and hyperplasia of the kallikrein-
producing cells and enhancing the excretion of urinary
kallikrein.11 In fact, high potassium intake has been shown to
increase renal kallikrein and kinin B2 receptor mRNAs and
the urinary levels of kinins in spontaneously hypertensive
rats.12 These potassium-induced changes have been reflected
in blood pressure reduction both in animals12 and humans13
at least under disease conditions.
The current study was designed to determine the blood
pressure profile, tissue expression and urinary activity of
kallikrein in a model of overload proteinuria and to evaluate
the protective changes produced by kallikrein stimulation.
Our results indicate a close relationship between elevation
of blood pressure and down regulation of renal kallikrein
in protein-overloaded animals, and the subsequent signifi-
cant correction of hypertension after enhancing its
synthesis and secretion with a high potassium diet.
Our hypothesis, for a participation of the kallikrein–kinin
system in the pathogenesis of hypertension in this model is
supported by the fact that the kinin B2 receptor antagonist,
HOE140, blunted the hypotensive benefits obtained by
potassium treatment.
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RESULTS
Proteinuria, tubulointerstitial damage, serum albumin, renal
function and electrolytes
The administration of 2 g bovine serum albumin (BSA), but
not vehicle, to healthy rats induced overt proteinuria, as
described by other authors.7 Total serum albumin was
significantly elevated in all BSA-injected groups compared
with the vehicle-injected one. Proteinuria was significantly
lower in the BSA-Kþ group after the seventh injection than
in the animals that received BSA alone; however, it was not
significantly different from the values shown by BSA-Kþ
-HOE140 rats (Table 1). Tubulointerstitial damage was
evident in all animals receiving BSA injections (BSA, BSA-
Kþ and BSA-Kþ -HOE140; Table 1), revealing proteinaceous
casts and interstitial infiltrates consisting almost entirely of
mononuclear cells. Fibrosis was not observed in any of the
groups studied. Severe lesions characterized by atrophy,
vacuolization and dilation were found in different tubules,
including distal nephron segments where kallikrein-produ-
cing cells are lodged. A meticulous observation of entire
sections demonstrated that glomeruli were not affected, as
has been described by others.14 Animals of the BSA-Kþ
group did not show significant differences in tubulointer-
stitial damage scores compared with the BSA group (Table 1).
The same degree of damage was observed in the BSA-Kþ
-HOE140-treated animals.
Renal function was not modified in BSA animals
compared with controls injected with the vehicle. The BSA-
Kþ group showed a mild but significant improvement in
creatinine clearance compared with the rats that did not
receive potassium (BSA group), or that received potassium
and the kinin B2 receptor antagonist.
Urinary potassium and chloride were very high in both
groups under high potassium diet (BSA-Kþ and BSA-Kþ
-HOE140), reflecting the high intake of potassium chloride.
Sodium excretion was not different in BSA animals compared
with vehicle-injected controls but, unexpectedly, the BSA-Kþ
group showed lower urinary sodium excretion than the BSA
animals without potassium. These lower values increased,
although not significantly, in the BSA-Kþ -HOE140 animals,
but did not reach the values observed in the vehicle or BSA
groups. Other parameters such as serum sodium, potassium
and chloride remained unchanged in all experimental groups.
Systolic blood pressure
No change in blood pressure was observed after the four
weeks of treatment with potassium (BSA-Kþ and BSA-Kþ
-HOE140) compared with their pre-potassium values (BSA-
Kþ : pre-potassium 12573.9 and post-potassium 1257
1.5 mmHg; BSA-Kþ -HOE140: pre-potassium 12272.1 and
post-potassium 12271.6 mmHg). Moreover, no differences
in systolic blood pressure (SBP) were observed between the
four groups before the intraperitoneal injections.
BSA-injected animals showed a significant increase after
the third dose, with values around 140 mmHg that remained
elevated at the last day of the experiment (Figure 1). In
contrast, control animals maintained their basal SBP, which
was around 120 mmHg after vehicle injections. BSA-Kþ rats
showed significantly lower values of SBP than the BSA group,
after both the third and the seventh injections. This reduction
in blood pressure was not observed when the kinin B2
receptor antagonist, HOE140 was added. Indeed, these rats
showed higher SBP values than those observed in the BSA
group (Figure 1).
Table 1 | Biochemical data, renal function and tubulointerstitial score damage after seventh injection
Vehicle BSA BSA-K+ BSA-K+-HOE140
Serum albumin (g/dl) 4.370.1 5.170.1* 5.070.1* 4.970.1*
Serum sodium (mmol/l) 14670.4 141+2.1 13870.7 14070.7
Serum potassium (mmol/l) 5.070.2 5.370.2 5.270.1 5.570.2
Serum chloride (mmol/l) 10270.4 9970.2 9770.4 10271.7
Urinary sodium (mmol/mg creatinine) 222729.4 2127 30.4 777 13.5*,# 106720.3*,#
Urinary potassium (mmol/mg creatinine) 123714.9 13076.9 232745.3*,# 465737.2*,#,@
Urinary chloride (mmol/mg creatinine) 291737.7 239718.3 481786.1# 685751.2*,#,@
Proteinuria (mg protein/mg creatinine) 0.770.35 203711.1* 10877.6*# 150.1716.4*
Creatinine clearance (ml/min) 659790 713722 826765# 6967131
Tubulointerstitial score 0.070.0 1.6870.13* 1.4270.17* 1.7870.10*
*Po0.05 (vs vehicle).
#Po0.05 (vs BSA).
@Po0.05 (vs BSA-K+).
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Figure 1 | Systolic blood pressure (SBP) profiles at different
stages of the experiment. SBP is expressed as mean7s.e. Vehicle
group, white bars; BSA group, black bars; BSA-Kþ , gray bars; BSA-Kþ -
HOE140 group, cross-hatched bars. *Po0.05 (vs vehicle); **Po0.05
(vs BSA); ***Po0.05 (vs BSA and vs BSA-Kþ ).
54 Kidney International (2006) 69, 53–59
o r i g i n a l a r t i c l e LG Ardiles et al.: Kallikrein in overload proteinuria
Renal kallikrein expression
Immunoreactive kallikrein was found exclusively in connect-
ing tubules of the distal nephron, as expected. No
immunostaining was observed when the antibody was
omitted or replaced by non-immune rabbit serum. A
significant reduction in immunoreactive renal kallikrein
was observed in BSA compared with vehicle rats, with
kallikrein-stained tubules dilated, their cells flattened, and
considerably less immunostained (Figure 2). The high
potassium intake resulted in significantly higher tissue
expression of the enzyme (BSA-Kþ rats), than that of
those treated with BSA alone; indeed, kallikrein-producing
cells reappeared bigger, with their typical cubic shape,
showing a staining intensity close to that observed in
the vehicle group (Figure 2). This improvement was not
affected by the treatment with HOE140. Quantification of
these differences with the aid of the image analyzer is shown
in Figure 3.
Urinary kallikrein activity
In order to corroborate former published results showing the
stimulatory effect of potassium treatment on renal kallikrein,
we measured urinary kallikrein activity before and after the
four-week period of potassium administration in the groups
BSA-Kþ and BSA-Kþ -HOE140, observing a significant
increase (BSA-Kþ : 30.074.2 mU/mg creatinine before
potassium, 48.372.1 mU/mg creatinine after potassium,
Po0.05. BSA-Kþ -HOE140: 35.173.9 mU/mg creatinine
before potassium, 61.472.5 mU/mg creatinine after potas-
sium, Po0.05).
The effect of protein overload on urinary kallikrein
activity was noted after the third and seventh injections in
the BSA group, showing a significant reduction compared
with the vehicle group. The effect of potassium intake was
also manifest in the BSA-Kþanimals that showed signifi-
cantly higher values of kallikrein excretion after the protein
overload than those of the BSA group. Similar kallikrein
values were observed in the presence of HOE140 (Figure 4).
Correlations
An inverse correlation was found between SBP and urinary
kallikrein activity after the third and seventh injections,
including vehicle, BSA, and BSA-Kþ rats in the analysis.
Moreover, a positive correlation was found between im-
munohistochemical kallikrein expression and enzymatic
urinary activity at the end of the experiment (Figure 5).
DISCUSSION
We have demonstrated a significant reduction in the
expression and secretion of renal kallikrein associated with
an increase in blood pressure in the overload proteinuria rat
model. Kallikrein, the pivotal enzyme of the renal kallik-
rein–kinin system, is synthesized in connecting tubule cells of
the distal nephron and secreted to the tubular lumen or into
the basolateral interstitium to release kinin peptides from
their multifunctional, endogenous, natural substrates, the
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Figure 2 | Morphological appearance of renal tissue at day seven
of vehicle, BSA, BSA-Kþ and BSA-Kþ -HOE140 rats. Left column (a,
c, e, g), hematoxylin–eosin staining. Right column (b, d, f, h),
immunoreactive kallikrein expression in representative kidney
sections obtained from vehicle, BSA, BSA-Kþ and BSA-Kþ -HOE140
animals (original magnification: a, b, d, e, f, h  200; c, g  100).
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Figure 3 | Kallikrein immunohistochemistry in vehicle, BSA, BSA-
Kþ and BSA-Kþ -HOE140 rats. Differences in kallikrein immunos-
taining (Kal-IHC) were quantified by an automated image analyzer.
Vehicle group, white bar; BSA group, black bar; BSA-Kþ , gray bar,
BSA-Kþ -HOE140 group, cross-hatched bars. *Po0.05 (vs vehicle);
**Po0.05 (vs BSA).
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renal kininogens (produced by collecting duct cells).15 The
paracrine formation of kinins affects renal blood flow,16
sodium and water excretion,10 and participates in blood
pressure regulation.17 Functional studies showing reduced
urinary kallikrein activity, specially in salt-intolerant hyper-
tensive subjects18 and renal hypertension,19 support the view
that kinins formed by renal tissue kallikrein may modulate
systemic blood pressure in humans.
What could be the explanation for the downregulation of
renal kallikrein during protein overload? First, confirming
previous reports,20 when an amount of BSA similar to that
found in the urine of the BSA-injected animals was added
to normal rat urine, no changes in enzymatic activity
were observed, excluding that BSA itself falsely reduced
the activity in the proteinuric group. Second, the presence
of an inhibitor in the urine of the exogenous protein
overloaded rats was also explored by adding increasing
amounts to urine samples obtained from the vehicle group,
but no inhibition of kallikrein activity was observed.
In addition, the proportion of active enzyme vs that
obtained after trypsin treatment of the samples was
identical in both groups (data not shown). Another reason
for the observed results may be the animal strain used
to perform the experiments. Traditionally, Lewis7,21 and
Wistar9 strains have been used. Eddy’s21 first report on the
protein-overload proteinuria rat model, using the Lewis
strain, mentioned anecdotal increases in blood pressure.
Therefore, we cannot rule out the possibility of a special
sensitivity of the Sprague–Dawley strain to develop hyperten-
sion when the synthesis and secretion of kallikrein are
reduced. Thus, significant tubular damage induced
by proteinuria, in the renal segment associated with
kallikrein production, is the most probable explanation for
its reduced synthesis in the renal parenchyma and secretion
into the urine. Proteinuria induces severe inflammatory
activation of proximal tubules to trigger tubulointerstitial
damage that will affect, by vicinity, all nephron segments.
Massive proteinuria, reaching the distal nephron, may have
also interfered with kallikrein synthesis by connecting
tubules. Potassium treatment, on the other hand, may have
selectively protected kallikrein-producing tubules, increasing
their mass to withstand facing the overload proteinuric
challenge.
The nature of the stimulatory effect of high potassium
intake on renal kallikrein cannot be elucidated from this
study, because both renal kallikrein and potassium excretion
are under a multihormonal regulation22 including miner-
alocorticoids, glucocorticoids and prostaglandins. The alter-
native of a direct stimulation of renal kallikrein by potassium
itself has also been proposed.11
We postulate the participation of the renal kallikrein–kinin
system in the pathogenesis of the blood pressure elevation
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Figure 4 | Urinary kallikrein activity levels in vehicle, BSA, BSA-
Kþ and BSA-Kþ -HOE140 rats. Urinary kallikrein activity (UKal)
values are expressed as means7s.e. Vehicle group, white bars; BSA
group, black bars; BSA-Kþ , gray bars; BSA-Kþ -HOE140 group, cross-
hatched bars. *Po0.05 (vs vehicle); **Po0.05 (vs BSA).
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Figure 5 | Scatterplots illustrating correlations between kallikrein
immunohistochemical expression (Kal-IHC), urinary kallikrein
activity (UKal) and systolic blood pressure (SBP) in vehicle, BSA
and BSA-K groups. (a) linear regression performed with data after
third and seventh injections; (b, c), linear regression using data after
seventh injection.
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observed in this animal model. Nowadays, when hyperten-
sion is considered a complex disorder with multiple factors
involved in its pathogenesis, we cannot ignore the strong
evidences about the activation of the renin–angiotensin–
aldosterone system and endothelin-1 in this model.9,23
We demonstrate here that downregulation of renal kallikrein
could establish an imbalance between actions of opposite
systems as has been proposed in other circumstances,24
favoring ideal conditions for a rise in blood pressure.
Considerable evidence indicates that the connecting tubule
cells, the place where renal kallikrein is synthesized, also
participate in potassium secretion.11 Because a high potas-
sium diet induces hypertrophy and hyperplasia of kallikrein-
producing cells, this may be the reason for the increase in
urinary kallikrein levels evidenced in our study prior to BSA
overcharge. When facing the overload proteinuria challenge,
the augmented mass of kallikrein-producing cells may give
rise to high amounts of kallikrein in the tubular lumen to
produce elevated kinin levels,12,25 which may counterbalance
the effects of vasoconstrictor peptide hormones. This
phenomenon was less evident after the seventh dose,
probably because the protective effect was overcome by a
cumulative predominance of prohypertensive factors acti-
vated during the evolution of renal damage. Supporting a
role for kinins in vascular tone regulation is the fact that
blood pressure levels were much higher in the BSA-Kþ
animals that received the kinin B2 receptor antagonist
HOE140. This antagonist may have induced a deeper
reduction of kinin action, leaving vasoconstrictor hormones
even less compensated. The strong correlations found
between blood pressure and both immunohistochemical
kallikrein expression and urinary kallikrein activity also
support our hypothesis.
As all our experiments were performed in animals under
normal salt intake, it is difficult to evaluate the occurrence of
salt-sensitivity as another factor involved in the pathogenesis
of hypertension in this model. Indeed, sodium urinary
excretion in the BSA group was not different from the vehicle
control group, and an unexpected low sodium excretion was
found in the BSA-Kþ group compared with BSA animals.
Sodium urinary levels did not change significantly after kinin
B2 receptor blocking. Although we do not have a satisfactory
explanation for this finding, it is against the alternative of salt
retention as a hypertensive mechanism.
We further confirmed that protein overload does not
significantly reduce creatinine clearance, as there were no
differences between BSA and vehicle control animals, suggest-
ing that this parameter could not account for the rise in blood
pressure. Consequently, our results suggest that an acute
vasodilator action may be the most likely explanation
for regulation of blood pressure by kinin peptides in
this model.
The significant reduction in the protein excretion rates
observed in the BSA-Kþ group deserve some additional
comments. Studies employing transgenic animals and
somatic gene delivery have shown that the expression of
the kallikrein transgene can induce not only prolonged
reduction of blood pressure,26 but also attenuation of renal
damage in animal models of renal injury associated with
hypertension.27 Furthermore, beneficial effects of angiotensin
I-converting enzyme inhibitors on renal fibrosis have been
attributed to elevated levels of kinins gained through
inhibition of angiotensin-converting enzyme.28–31 It is
possible that potassium treatment, through a reduction in
blood pressure levels, may induce a reduction in proteinuria
merely by a hemodynamic effect and the question of whether
renal kallikrein or kinins per se might have an effect on the
renal parenchyma cannot be answered by our study. The
higher levels of proteinuria showed by the BSA-Kþ -HOE140
group did not reach statistical significance with the BSA-Kþ
group and do not help to solve this issue because these
animals also had high blood pressure. Histological analysis
was not helpful on this issue because we could not
demonstrate significant improvement on tubulointerstitial
damage scores in BSA-Kþ animals, and fibrosis was not
observed as it has been described in other experimental
models.32 More prolonged experiments might answer this
interesting point. Lastly, we cannot exclude that a high
potassium intake might protect against proteinuria irrespec-
tive of changes in renal kallikrein and blood pressure; indeed,
it has been shown that potassium supplementation may
attenuate renal injury in spontaneously hypertensive rats
without affecting blood pressure.25
Another issue to comment on is whether kallikrein
stimulation may reduce blood pressure in normal animals.
It has been reported that dietary potassium chloride may
blunt blood pressure rise in spontaneously hypertensive rats
but not in normotensive Wistar–Kyoto rats;33,34 the absence
of changes in blood pressure under potassium treatment, at
the beginning of the experiment (before BSA injection), does
not support that hypothesis.
Finally, an indemnity of the renal kallikrein–kinin system
may be of crucial importance to maintain vasoconstrictor/
vasodilator equilibrium to regulate vascular tone. The link
between our results and human nephrotic syndrome deserves
further clinical studies.
MATERIALS AND METHODS
Animals and experimental procedures
All experimental procedures were approved by the Universidad
Austral Animals Ethics Committee. Sprague–Dawley normotensive
female healthy rats (aged 6–12 weeks, weighing 18177.3 g) were
obtained from our University Breeding Center (Department of
Histology and Pathology, Universidad Austral de Chile). Overload
proteinuria, without previous nephrectomy (to avoid the effects of
renal mass reduction), was induced as previously described.14,35,36,21
Animals maintained at constant room temperature with a 12 h
light/dark cycle, fed with normal sodium rat chow and with free
access to water were randomized into five groups:
K Vehicle-injected controls (n¼ 5). This group received seven 0.9%
saline intraperitoneal (i.p). injections, 6 ml daily.
K Bovine serum albumin (BSA) group (n¼ 7). This group received
seven daily i.p. injections of 2 g BSA (Fraction V, A-4503,
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Sigma), given as 6 ml of a 33.3% albumin solution dissolved in
0.9% sterile saline.
K Potassium-treated animals. This group (n¼ 14) included animals
that received 2% potassium chloride in the drinking water for four
weeks before and during the period of BSA injections to induce
stimulation of renal kallikrein synthesis. After the first four weeks
of potassium, they were divided into two groups:
K BSA-Kþgroup (n¼ 7). Injected in the same schedule as the BSA
group, and maintaining administration of potassium cloride 2%
during the injections.
K BSA-Kþ -HOE140 group (n¼ 7). Received BSA injections and
potassium in the same schedule as BSA-Kþ but the night before
the first injection of albumin osmotic subcutaneous minipumps
were installed to deliver 500 micrograms/kg/day of the kinin B2
receptor antagonist HOE140 (Icatibants Aventis, Frankfurt,
Germany) along the period of BSA injections.
Blood pressure, urine and sera collection, and tissue
preparation
Tail-cuff SBP was measured in prewarmed conscious animals in basal
conditions, after potassium treatment when appropriate, and after the
third and seventh injections using an Ultrasonic Doppler Flow
Detector 811–B (PARKS Electronic Inc., OR, USA). Five readings were
obtained at each time point, and a mean was recorded for each rat.
Twenty-four-hour urine collections for proteinuria, creatinine,
electrolytes and kallikrein activity were performed in individual
metabolic cages, while food was withheld to avoid fecal contamina-
tion and water was offered ad libitum (2% potassium in tap water for
the BSA-Kþ and BSA-Kþ -HOE140 groups). The animals were killed
at 24 h after the seventh injection, by aortic exsanguination under
ether anesthesia. Serum was obtained for biochemical analysis and
kidneys were removed, washed with saline, and horizontal slices were
fixed in 4% formalin–PBS, and embedded in paraffin wax.
Urine and serum chemistry
Proteinuria was measured using a turbidimetric method (U/CSF Protein,
Roche Diagnostics GmbH, Mannheim, Germany), electrolytes in an ion-
selective autoanalyzer, and creatinine by modification of the Jaffe´ reaction
in samples obtained after the seventh injection of BSA. Total serum
albumin was measured by bromcresol green in an autoanalyzer.
Proteinuria and urinary electrolytes are expressed as milligram/milligram
urinary creatinine to avoid differences in urinary volumes.
Histological evaluation of tubulointerstitial lesions
Severity of tubular dilation, atrophy and cellular infiltration was
evaluated on hematoxylin–eosin-stained sections, determining the
percentage in the section affected by the corresponding finding.
Gradation of damage (0 to 4þ ) was performed by modifying the
scale of Zoja et al.,37 where 0¼ changes in less than 10% of the
histological section; 1þ ¼ changes in up to 25%; 2þ ¼ changes in
up to 50%; 3þ ¼ changes in up to 75%; 4þ ¼ changes in more
than 75% of the section. The entire cortical region of the section was
examined and the average score obtained in each biopsy was used as
‘TI score’, as previously published.38 The Masson’s trichromic
staining was used to assess the level of fibrosis.
Immunohistochemistry
Tissue sections (5mm thick) were dewaxed, hydrated, washed three
times with 50 mM Tris-HCl pH 7.8 and then incubated with a rabbit
anti-rat-urinary-kallikrein antibody diluted at 1:40 000 with the
same buffer containing 1% immunoglobulin-free BSA. The cross-
reactivity of this antiserum, assessed by dot-blot immunoassay, was
strong for rK1, moderate for rK2 and rK7 and minimal for rK9.39
Additional controls included omission of the anti-kallikrein serum
and its replacement by nonimmune rabbit serum at the same
dilution. Bound rabbit immunoglobulins were detected using the
LSABþHRP System (Dako, Carpinteria, CA, USA). The percentage
and intensity of the labeled surface area was evaluated by using the
KS 300 imaging system 3.0 (Zeiss, Mu¨nchen-Hallbergmoos,
Germany). The degree of staining was calculated by the ratio of
suitable binary threshold image and the total field area, integrating
the intensity of the staining in the specific areas. Performing the
readings in this way allows one to avoid potential differences in the
amount of total tissue examined. For each sample, a mean value was
obtained by analysis of 20 different fields (at  20), excluding
glomeruli and blood vessels. The procedure was performed twice,
independently, and inter-assay variability was not significant. The
staining score was expressed as density/mm2. This way of
quantifying immunohistochemical assays has been validated in
previous publications of our group.38
Urinary kallikrein assay
Urinary kallikrein activity was determined by the amidase method
using the synthetic substrate D-Val-Leu-Arg-p-nitroanilide (Sigma
Aldrich, St Louis, MO, USA)40 in the presence of a mixture of
inhibitors (EDTA and soybean trypsin inhibitor, Sigma Aldrich) to
block all other kallikrein-like activities. Control experiments have
shown that these inhibitors have no effect on enzymatic activity of
purified rat salivary and human urinary kallikreins. Moreover,
enzymatic activity obtained under these conditions was completely
abolished by antikallikrein antiserum, but not by non-immune
serum, indicating that it in fact corresponds to kallikrein activity.41
Values, obtained in milliunits/milliliter, were corrected by milligram
of urinary creatinine to avoid differences in volume.
Statistical analysis
The nonparametric Mann–Whitney test was used to analyze
differences between groups. After proving normal distribution,
correlations between variables were tested by linear regression.
Values are expressed as mean7s.e. and P-values o0.05 were
considered significant. A commercial statistical package (GraphPad
InStats version 3.01 for Windows 95/NT, San Diego, CA, USA) was
used.
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